Costs and Outcomes of Clostridioides difficile Infections in Germany: A Retrospective Health Claims Data Analysis
CDI in Germany is associated with a high clinical and economic burden, including significantly higher mortality, costs, and healthcare resource utilization, in patients with CDI versus their matched patients without CDI. This has important implications for patients, healthcare providers, and the healthcare system.
Authors
- Kirstin Heinrich (ORCID: https://orcid.org/0000-0002-2973-8864)
- Jennifer C. Moïsi (ORCID: https://orcid.org/0000-0002-7137-5630)
- Dennis Häckl (ORCID: https://orcid.org/0000-0001-8542-693X)
- Katharina Schley (ORCID: https://orcid.org/0000-0002-0975-4154)
- Gordon Brestrich (ORCID: https://orcid.org/0000-0002-1306-5474)
- Dominik Obermüller
- Christof von Eiff (ORCID: https://orcid.org/0000-0002-7821-2359)
- Thomas Weinke
Institutions
- Pfizer (United States) (US)
- Pfizer (Germany) (DE)
- Institute for Applied Economic Research (DE)
- Pfizer (France) (FR)
- Klinikum Ernst von Bergmann (DE)
- Impact Technology Development (United States) (US)
Publication Details
- Journal
- Infectious Diseases and Therapy
- Published
- 2024-11-20
- DOI
- https://doi.org/10.1007/s40121-024-01075-1
- Citations
- 1
- Primary Topic
- Clostridium difficile and Clostridium perfringens research
- Type
- article
- Field-Weighted Citation Impact
- 0.39
Funders
- Pfizer